Recent patents on inflammation & allergy drug discovery最新文献_第10页

Ursolic Acid and Oleanolic Acid: Pentacyclic Terpenoids with Promising Anti-Inflammatory Activities. 熊果酸和齐墩果酸：具有良好抗炎活性的五环萜类化合物

IF 4.2

Recent patents on inflammation & allergy drug discovery Pub Date : 2016-01-01 DOI: 10.2174/1872213x10666160711143904

Dharambir Kashyap, Ajay Sharma, Hardeep S Tuli, Sandeep Punia, Anil K Sharma

{"title":"Ursolic Acid and Oleanolic Acid: Pentacyclic Terpenoids with Promising Anti-Inflammatory Activities.","authors":"Dharambir Kashyap, Ajay Sharma, Hardeep S Tuli, Sandeep Punia, Anil K Sharma","doi":"10.2174/1872213x10666160711143904","DOIUrl":"10.2174/1872213x10666160711143904","url":null,"abstract":"Background: Plant derived products are not only served as dietary components but also used to treat and prevent the inflammatory associated diseases like cancer. Among the natural products pentacyclic terpenoids including ursolic acid and oleanolic acid are considered as the promising anti-inflammatory therapeutic agents.Objectives: The current review extensively discusses the anti-inflammatory therapeutic potential of these pentacyclic moieties along with their proposed mechanisms of action. Furthermore, the relevant patents have also been listed to present the health benefits of these promising therapeutic agents to pin down the inflammatory diseases. Expert opinion: Pentacyclic terpenoids are known to negatively down-regulate a variety of extracellular and intracellular molecular targets associated with disease progression. The major anti-inflammatory effects of these molecules have been found to be mediated via inactivation of NFkB, STAT3/6, Akt/mTOR pathways. A number of patents on UA & OA based moieties have been reported between 2010 and 2016. Still there have been only a few compounds which meet the need of sufficient hydro solubility and bioavailability along with higher anti-inflammatory activities. Thus, it is essential to develop novel derivatives of terpenpoids which may not only overcome the solubility issues but also may improve their therapeutic effects. In addition, scientific community may utilize nanotechnology based drug delivery systems so as to increase the bio-availability, selectivity and dosages related problems.","PeriodicalId":20960,"journal":{"name":"Recent patents on inflammation & allergy drug discovery","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34312359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 104

Role of Galectins in Allergic Disorders. 半凝集素在过敏性疾病中的作用。

IF 4.2

Recent patents on inflammation & allergy drug discovery Pub Date : 2016-01-01 DOI: 10.2174/1872213x10666160426152917

Umut C Kucuksezer, Cevdet Ozdemir

{"title":"Role of Galectins in Allergic Disorders.","authors":"Umut C Kucuksezer, Cevdet Ozdemir","doi":"10.2174/1872213x10666160426152917","DOIUrl":"https://doi.org/10.2174/1872213x10666160426152917","url":null,"abstract":"Background: Allergen avoidance, pharmacotherapy; with antihistamines, anti-leukotrienes, corticosteroids and bronchodilators.as well as monoclonal antibodies; and allergen specific immunotherapy stand as confirmed approaches for the management of allergic disorders as asthma, allergic rhinitis/rhinoconjunctivitis, atopic dermatitis, food allergies and anaphylaxis. Galectins are members of animal lectin protein family, with binding specificity for β-galactoside sugars. These highly conserved proteins are known to be expressed in various effector cells of the immune system, exert immuno-regulatory activities, and enroll in tissue inflammation and regulation of immune homeostasis.Objective: This review aims to explain the galectin family and influence of galectins in the immune mechanisms of allergic disorders.Results: Galectins have multiple roles in innate and adaptive immunity. Intense research in the field of immunology related with galectins have given rise to several patent applications. Those, increasing in vivo efficacy of galectins for therapeutic applications, utilizing galectins for immune stimulation and prolongation of immune responses, utilization of them as disease markers are pioneers. As immune cells can be targeted by galectins, cells containing these molecules can be used for immune intervention. Regulation of cytokine productions by immune cells as IL-1β and IL-10 as well as dendritic cell functions by galectins may be efficient in limitation of some immune-mediated disorders.Conclusion: Taken all together, better learning of galectin biology together with detailed revealing of galectin-immune system interactions have great potential for immune interventions targeting allergy-related disorders.","PeriodicalId":20960,"journal":{"name":"Recent patents on inflammation & allergy drug discovery","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34430658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Determinants of Grip Strength in Tunisian Nurses: A Bicentric Study. 突尼斯护士握力的决定因素:双中心研究。

IF 4.2

Recent patents on inflammation & allergy drug discovery Pub Date : 2016-01-01 DOI: 10.2174/1872213x10666160607125547

Irtyah Merchaoui, Lamia Bouzgarrou, Charfeddine Amri, Mohamed Akrout, Jacques Malchaire, Sana El Mhamdi, Neila Chaari

{"title":"Determinants of Grip Strength in Tunisian Nurses: A Bicentric Study.","authors":"Irtyah Merchaoui, Lamia Bouzgarrou, Charfeddine Amri, Mohamed Akrout, Jacques Malchaire, Sana El Mhamdi, Neila Chaari","doi":"10.2174/1872213x10666160607125547","DOIUrl":"https://doi.org/10.2174/1872213x10666160607125547","url":null,"abstract":"Background: Grip muscle force has always been used to assess functional limitations in elderly. Its use as a tool to assess work capacity has never been described in the literature.Objective: To describe the patent determinants of grip strength and the usefulness of its measurement in assessing workability index in the healthcare sector.Methods: This is a cross-sectional study conducted in a sample of 293 healthcare workers representative of 1181 based on a comprehensive questionnaire about socio-professional characteristics and on an 8-item work capacity evaluation (WAI). Besides, Body mass index was measured and muscle strength was assessed by JAMAR hydraulic dynamometer.Results: Handgrip Strength was stronger in male nurses (p < 0.001), with low perceived physical load (p = 0.0001) and working on a night shift (p = 0.001). It decreased with a greater duration of household work (p < 0.0001) and increased with a greater BMI (p = 0.015) and a better workability index (p < 0.0001). After removal of all the variables that were not independently associated with the muscle strength force, factors accounting for 52.6% of the variance in nurses handgrip strength were gender (p < 0.001), workability index (p < 0.001), duration of household work (p = 0.021), BMI (p = 0.002), perceived physical load (p < 0.001) and work schedule (p = 0.002).Conclusion: Grip Strength Test is a useful tool to assess strength and functional capacity at work in healthcare workers. Further longitudinal studies are required to confirm this hypothesis.","PeriodicalId":20960,"journal":{"name":"Recent patents on inflammation & allergy drug discovery","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1872213x10666160607125547","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34562557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Actinic Keratosis Pathogenesis Update and New Patents. 光化性角化病发病机制最新进展及新专利。

IF 4.2

Recent patents on inflammation & allergy drug discovery Pub Date : 2016-01-01 DOI: 10.2174/1872213x10666160504104825

Carmen Cantisani, Giovanni Paolino, Marcello Melis, Valentina Faina, Federico Romaniello, Dario Didona, Michele Cardone, Stefano Calvieri

引用次数: 11

Recent Patents for the Treatment of Asthma. 治疗哮喘的最新专利。

IF 4.2

Recent patents on inflammation & allergy drug discovery Pub Date : 2016-01-01 DOI: 10.2174/1872213x10666160603144528

David El-Qutob, Isabela Raducan

{"title":"Recent Patents for the Treatment of Asthma.","authors":"David El-Qutob, Isabela Raducan","doi":"10.2174/1872213x10666160603144528","DOIUrl":"https://doi.org/10.2174/1872213x10666160603144528","url":null,"abstract":"Background: Despite adequate adherence and completion of anti-asthmatic treatment, many patients remain poorly controlled or uncontrolled. Asthma management is based on the use of medication to reverse the bronchial obstruction and eliminate the airway inflammation. New drug development is expected in the future as a consequence of discoveries in the pathophysiology and mechanisms of asthma. Currently, a good and effective set of treatments is available for these diseases. However, the search for new treatment modalities to improve the currently available is especially important for those patients unresponsive to current therapy.Objective: In this review, we summarize new anti-cytokines therapies, anti-leucotrienes molecules, immunomodulatory and anti-inflammatory agents, researched for treatment of asthma.Method: Database patents were used for searching new patents from 2015 and from the beginning of 2016 about treatment of asthma.Conclusion: Pharmacogenomic point of view is now being considered by most major pharmaceutical companies as line of investigation without end in the nearest horizon. Pharmacogenomics has the potential to notably improve the safety and effectiveness of medications.","PeriodicalId":20960,"journal":{"name":"Recent patents on inflammation & allergy drug discovery","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34612423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacokinetics and Systemic Activity of a New Patent of an Inhaled Corticosteroid/Long-Acting β2-Agonist Combination for Use in Asthma Therapy: Fluticasone Furoate/Vilanterol Trifenatate. 吸入皮质类固醇/长效β2激动剂组合用于哮喘治疗的新专利:糠酸氟替卡松/三氟乙酸维兰特罗的药代动力学和全身活性

IF 4.2

Recent patents on inflammation & allergy drug discovery Pub Date : 2015-07-31 DOI: 10.2174/1872213X10666151119144907

O. D. Wolthers

{"title":"Pharmacokinetics and Systemic Activity of a New Patent of an Inhaled Corticosteroid/Long-Acting β2-Agonist Combination for Use in Asthma Therapy: Fluticasone Furoate/Vilanterol Trifenatate.","authors":"O. D. Wolthers","doi":"10.2174/1872213X10666151119144907","DOIUrl":"https://doi.org/10.2174/1872213X10666151119144907","url":null,"abstract":"The present paper reviews pharmacokinetics and systemic activity of a new patent of fluticasone fumarate/vilanterol trifenatate and summarises the efficacy data in children, adolescents and adults with asthma. Bioavailability of oral deposition of fluticasone furoate is approximately 1%, of oral and pulmonary deposition 15%. Fluticasone furoate 400, 600 and 800 µg have been associated with reductions in 24h urine cortisol excretion in adults, whereas several studies on fluticasone furoate/ vilanterol trifenatate 100/25 µg and 200/25 µg once daily found no suppressive effects. Bronchodilation was detected in adults with asthma from 5 minutes after vilanterol trifenatate was inhaled and up to 24 hours after. Five large clinical trials which were sponsored by the manufacturer GlaxoSmithKline provided evidence that dry powder fluticasone furoate/vilanterol trifenatate 100/25 µg and 200/25 µg once daily are efficacious in asthma in patients ≥ 12 years of age. It remains to be proven, however, that once daily dosing may improve asthma control as compared to twice daily dosing. Efficacy and the systemic activity potential for hypothalamic-pituitary-adrenal and growth suppression of fluticasone furoate have not been established in children. The potential for systemic activity of fluticasone furoate in children may be assessed by knemometry.","PeriodicalId":20960,"journal":{"name":"Recent patents on inflammation & allergy drug discovery","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2015-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68047553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Recent Patents of Complementary and Alternative Medicine for Allergic Rhinitis. 变应性鼻炎补充和替代药物最新专利。

IF 4.2

Recent patents on inflammation & allergy drug discovery Pub Date : 2015-07-31 DOI: 10.2174/1872213X10666151119144718

K. Hon, C. Fung, A. Leung, H. Lam, S. L. Lee

{"title":"Recent Patents of Complementary and Alternative Medicine for Allergic Rhinitis.","authors":"K. Hon, C. Fung, A. Leung, H. Lam, S. L. Lee","doi":"10.2174/1872213X10666151119144718","DOIUrl":"https://doi.org/10.2174/1872213X10666151119144718","url":null,"abstract":"Allergic rhinitis (AR) is a common respiratory disease affecting both adults and children worldwide. Affected patients may experience nasal congestion/stuffiness, rhinorrhea (anterior and/or posterior), nasal/ nasopharyngeal itching and sneezing. Allergen avoidance is the principal step in the management. Nasal saline irrigation to remove allergen (s) in the nose is a useful adjunctive therapy in the management of moderate to severe AR. Symptomatic relief and improved quality of life may be achieved in the majority of patients with appropriate pharmacotherapy. Mild-to-moderate cases are usually managed with either an oral second generation antihistamine or an intranasal corticosteroid. More severe cases may require treatment with an intranasal corticosteroid in combination with various oral medications. Patients who require medications for more than 6 months per year or have intolerable side effects from pharmacotherapy can be considered for immunotherapy. A wide range of complementary and alternative medicines (CAM) have also been proposed. This overview evaluates the evidence of use of CAM for AR. Some methods including acupuncture and herbal medicine have supportive evidence, but the efficacy of other CAM is controversial. Conversely, possible side effects of different modalities are often inadequately documented. The herbal formulae include Butterbur, Nigella sativa, Shi-Bi-Lin, Polyherbal formula, Grapeseed extract, Rosmarinic acid, Spirulina, Biminne, and Bhu-zhong-yi-qi-tong. Further research is needed to assess the efficacy and safety before they are employed in treating AR. This review article also discusses recent CAM patents for use in AR, which are exclusively traditional Chinese medicine (TCM) concoctions primarily for oral consumption but two as topical spray. Only 8 pertinent patents, all TCM compositions for treating AR and registered in 2014, were obtained. Description about their efficacy is impressive but objective outcome evaluation tools are lacking.","PeriodicalId":20960,"journal":{"name":"Recent patents on inflammation & allergy drug discovery","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2015-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68047541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 15

Neuropsychological Effects of Mercury Exposure Among Dentists in Monastir City. 莫纳斯提尔市牙医汞暴露的神经心理影响。

IF 4.2

Recent patents on inflammation & allergy drug discovery Pub Date : 2015-07-31 DOI: 10.2174/1872213X10666151119145142

N. Chaari, S. Chebel, I. Merchaoui, A. Kerkeni, F. Neffati, F. Najjar, M. Akrout

{"title":"Neuropsychological Effects of Mercury Exposure Among Dentists in Monastir City.","authors":"N. Chaari, S. Chebel, I. Merchaoui, A. Kerkeni, F. Neffati, F. Najjar, M. Akrout","doi":"10.2174/1872213X10666151119145142","DOIUrl":"https://doi.org/10.2174/1872213X10666151119145142","url":null,"abstract":"AIMS\u0000The aim of this study is to assess the neuropsychological manifestations of mercury exposure in dentists.\u0000\u0000\u0000METHODS\u0000A cross-sectional study was carried out including 64 dentists matched to a control group according to age and gender. This study protocol included a neurological evaluation, a questionnaire assessing the study groups' general characteristics and personal factors that may affect mercury urinary excretion in both groups. EUROQUEST questionnaire and Hospital Anxiety and Depression scale (HADS) were used to evaluate the neuropsychological symptoms reported during the last 12 months. In both groups, mercury impregnation was assessed by monitoring urinary mercury.\u0000\u0000\u0000RESULTS\u0000In the exposed group, scores of neurological symptoms, memory disturbances and anxiety were found to be significantly higher than those in controls (p < 0.01). Mean scores of HAD Depression's scale were higher in the exposed group than in controls. Most of the neurotoxic manifestations were correlated to the levels of urinary mercury excretion in the exposed group. Mean levels of urinary mercury were significantly higher in the dentists group than in controls, with respective values of 21.1 ± 19.6 µg/g of creatinine and 0.05 ± 0.9 µg/g of creatinine. In nine dentists having urinary mercury levels higher than 35 µg/g of creatinine, neurological examination showed a bilateral and symmetric intentional tremor in both upper limbs. In the exposed group, the neuropsychological manifestations and levels of urinary mercury were found to be significantly correlated.\u0000\u0000\u0000CONCLUSION\u0000Increased levels of urinary mercury observed in dentists suggest that exposure to mercury vapour emissions adversely affects dental professionals, therefore prevention measures should be strengthened, with a special medical supervision program of dentists exposed to mercury vapours should be implemented. We have also outlined some relevant patents in this article.","PeriodicalId":20960,"journal":{"name":"Recent patents on inflammation & allergy drug discovery","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2015-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68047040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 8

Vaccines. 疫苗。

IF 4.2

Recent patents on inflammation & allergy drug discovery Pub Date : 2015-01-01 DOI: 10.2174/1872213x09666150220100549

Juan B De Sanctis

引用次数: 0

Complementary and alternative medicine for childhood asthma: an overview of evidence and patents. 儿童哮喘的补充和替代药物:证据和专利概述。

IF 4.2

Recent patents on inflammation & allergy drug discovery Pub Date : 2015-01-01 DOI: 10.2174/1872213x09666150302105225

Kam-Lun E Hon, Ching Ki Fung, Alexander K C Leung, Theresa Ngan-Ho Leung, Daniel K K Ng

{"title":"Complementary and alternative medicine for childhood asthma: an overview of evidence and patents.","authors":"Kam-Lun E Hon, Ching Ki Fung, Alexander K C Leung, Theresa Ngan-Ho Leung, Daniel K K Ng","doi":"10.2174/1872213x09666150302105225","DOIUrl":"https://doi.org/10.2174/1872213x09666150302105225","url":null,"abstract":"Asthma is a prevalent childhood atopic disease associated with significant impairment of quality of life. Management relies on avoidance of triggers such as food and aeroallergens, the use of inhaled bronchodilators/corticosteroids and anti-allergic or immune-modulating therapies. Inhaled corticosteroids (ICSs) and bronchodilators have been the mainstay of treatment. In China as well as throughout Asia, myths and misconceptions on western medicine and corticosteroids are prevalent and result in non-adherence of treatment. A wide variety of complementary and alternative medicines (CAM) are available. Some of these have undergone extensive clinical trials and have been documented to have some therapeutic effects on asthma. Nevertheless, the majority of these treatment modalities is not efficacious and may even be detrimental. This article overviews the evidence for the clinical efficacy of all major CAM modalities. Despite CAM modalities are extensively used by the patients with asthma, very few CAM patents are available. This article also discusses recent patents pertinent to asthma. Only a few patents on herbal medicine for asthma have been evaluated but therapeutic efficacy is not substantially documented. Parents seeking CAM for asthma must consult qualified registered practitioners before using it. ","PeriodicalId":20960,"journal":{"name":"Recent patents on inflammation & allergy drug discovery","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1872213x09666150302105225","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33096405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 14